Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PM...
Saved in:
| Published in | Immunologic research Vol. 73; no. 1; p. 11 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.12.2025
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45
+
CD33
low
HLA-DR
−
CD36
+
PMN-MDSC-like cells and mature CD13
+
CD11b
+
CD10
+
neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in
FLT3
-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. |
|---|---|
| AbstractList | Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45
+
CD33
low
HLA-DR
−
CD36
+
PMN-MDSC-like cells and mature CD13
+
CD11b
+
CD10
+
neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in
FLT3
-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients' prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45 CD33 HLA-DR CD36 PMN-MDSC-like cells and mature CD13 CD11b CD10 neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45+CD33lowHLA-DR−CD36+ PMN-MDSC-like cells and mature CD13+CD11b+CD10+ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45⁺CD33ˡᵒʷHLA-DR⁻CD36⁺ PMN-MDSC-like cells and mature CD13⁺CD11b⁺CD10⁺ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients' prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45+CD33lowHLA-DR-CD36+ PMN-MDSC-like cells and mature CD13+CD11b+CD10+ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML.Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients' prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45+CD33lowHLA-DR-CD36+ PMN-MDSC-like cells and mature CD13+CD11b+CD10+ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML. |
| ArticleNumber | 11 |
| Author | Sant’Ana, Alexia N. Figueiró, Fabrício Michalowski, Mariana B. Meirelles, Maria F. Dias, Camila K. Alegretti, Ana P. Portela, Pâmela Calvache, Ebellins T. Farias, Mariela G. Nunes, Vitória B. S. Daudt, Liane E. Paz, Alessandra A. |
| Author_xml | – sequence: 1 givenname: Alexia N. surname: Sant’Ana fullname: Sant’Ana, Alexia N. organization: Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS – sequence: 2 givenname: Camila K. surname: Dias fullname: Dias, Camila K. organization: Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS – sequence: 3 givenname: Vitória B. S. surname: Nunes fullname: Nunes, Vitória B. S. organization: Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS – sequence: 4 givenname: Mariela G. surname: Farias fullname: Farias, Mariela G. organization: Unidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre – sequence: 5 givenname: Ana P. surname: Alegretti fullname: Alegretti, Ana P. organization: Setor de Inovação, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre – sequence: 6 givenname: Pâmela surname: Portela fullname: Portela, Pâmela organization: Unidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre – sequence: 7 givenname: Ebellins T. surname: Calvache fullname: Calvache, Ebellins T. organization: Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre – sequence: 8 givenname: Maria F. surname: Meirelles fullname: Meirelles, Maria F. organization: Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre – sequence: 9 givenname: Liane E. surname: Daudt fullname: Daudt, Liane E. organization: Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Programa de Pós-Gradução em Saúde da Criança e do Adolescente, UFRGS – sequence: 10 givenname: Mariana B. surname: Michalowski fullname: Michalowski, Mariana B. organization: Programa de Pós-Gradução em Saúde da Criança e do Adolescente, UFRGS, Serviço de Oncologia Pediátrica, Hospital de Clínicas de Porto Alegre – sequence: 11 givenname: Alessandra A. surname: Paz fullname: Paz, Alessandra A. organization: Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre – sequence: 12 givenname: Fabrício surname: Figueiró fullname: Figueiró, Fabrício email: fabricio.figueiro@ufrgs.br organization: Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39673675$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUuLFDEQgIOsuLOrf8CDBLx4iebRebQ3WXzBgh4UvDWZpHo2u-mkTboX5k_4m804uwoexBwqofJVhcp3hk5SToDQU0ZfMkr1q8o45YpQ3hHaS2mIeoA2TMqeUC3lCdpQLjXhWn87RWe1XlPKVNeJR-hU9EoLpeUG_fhc8i7lugSHb21cAecRT3uIOXjioYRb8Liu81yg1lxIDDeAHcRYcUjYunWBexxHWG9gCvZ1u6phd7VUPJY84TBNa8rzFaS87OeQdtgmj10MKTgbsculQLRLyKk-Rg9HGys8udvP0dd3b79cfCCXn95_vHhzSZyQ_UKcEo5SY8FK3W-9NJx2YgvStmxnOGemHT20qKk1RmjmjfXOWzBKdf0oztGLY9-55O8r1GWYQj2MZRPktQ6CyY63D6L8P9BOaa07Khr6_C_0Oq8ltUEOVFvUMNWoZ3fUup3AD3MJky374V5KA_gRcCXXWmD8jTA6HMwPR_NDMz_8Mj8cuopjUW1w2kH58_Y_qn4Cf02y9A |
| Cites_doi | 10.7150/thno.36037 10.1002/cyto.b.20008 10.1007/s00277-013-1744-y 10.1158/1078-0432.CCR-19-3003 10.3389/fonc.2020.00109 10.1182/blood-2012-08-449918 10.1007/s00018-013-1286-4 10.1186/s12885-018-5086-y 10.1038/leu.2012.122 10.1111/bjh.16310 10.1007/s00432-022-03957-8 10.1172/JCI129204 10.26508/lsa.202000893 10.1084/jem.20201803 10.1007/s11684-020-0797-2 10.1016/j.ejca.2021.03.011 10.1182/blood-2016-08-733196 10.3324/haematol.2021.280161 10.1200/JCO.2012.42.2907 10.1073/pnas.1116110108 10.1126/sciimmunol.aaf8943 10.1158/1078-0432.CCR-17-3726 10.18632/oncotarget.24397 10.1080/2162402X.2017.1344804 10.1002/eji.200939486 10.1111/jcmm.17576 10.1016/j.celrep.2014.12.039 10.1016/j.blre.2021.100905 10.1016/j.immuni.2021.04.004 10.1038/leu.2012.120 10.3389/fonc.2021.656218 10.1189/jlb.0310162 10.1038/nrdp.2016.10 10.1182/blood-2013-02-484097 10.1111/cas.14274 10.1093/rheumatology/keac374 10.1007/s12308-014-0198-z 10.1007/s11864-020-00765-5 10.1158/1078-0432.CCR-14-2742 10.1038/s41375-021-01350-x 10.18632/oncotarget.12278 10.1182/blood-2018-03-836528 10.18632/oncotarget.8507 10.1002/cam4.3360 10.1038/s41392-021-00670-9 10.1182/blood.2019004537 10.1038/s41590-017-0022-x 10.1038/ncomms12150 10.1016/j.cger.2019.03.001 10.1038/s41416-018-0333-1 10.1182/blood.v97.1.89 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. Copyright Springer Nature B.V. Dec 2025 |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. – notice: Copyright Springer Nature B.V. Dec 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 K9. M7N 7X8 7S9 L.6 |
| DOI | 10.1007/s12026-024-09558-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts AGRICOLA MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1559-0755 |
| EndPage | 11 |
| ExternalDocumentID | 39673675 10_1007_s12026_024_09558_6 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Fundo de Incentivo à Pesquisa - Hospital de Clínicas de Porto Alegre grantid: FIPE/HCPA project nº 2021-0512 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico grantid: CNPq n°406035/2021-0 funderid: http://dx.doi.org/10.13039/501100003593 – fundername: Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul grantid: FAPERGS/PQG Grant nº 21/2551-0001972-7 funderid: http://dx.doi.org/10.13039/501100004263 – fundername: Instituto Nacional de Ciência e Tecnologia grantid: INCT/CNPq/CAPES/FAPERGS Grant nº 465671/2014-4 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico grantid: CNPq n°406035/2021-0 – fundername: Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul grantid: FAPERGS/PQG Grant nº 21/2551-0001972-7 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3SX 3V. 4.4 406 408 40D 40E 53G 5GY 5RE 5VS 67N 6NX 78A 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACUDM ACZOJ ADBBV ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HCIFZ HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LK8 LLZTM M1P M7P MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS O9- O93 O9G O9I O9J OVD P19 PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RKO ROL RPX RSV S16 S1Z S26 S27 S28 S3A S3B SAP SBY SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK6 WK8 Y6R YLTOR Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~A9 ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7T5 7U9 ABRTQ H94 K9. M7N 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c359t-c63c008aea579bd582043be5ac004822185acde85a70a88371d8adcdae86649f3 |
| IEDL.DBID | U2A |
| ISSN | 0257-277X 1559-0755 |
| IngestDate | Fri Jul 11 10:40:54 EDT 2025 Fri Jul 11 12:23:55 EDT 2025 Fri Jul 25 19:01:14 EDT 2025 Thu Apr 03 07:00:25 EDT 2025 Tue Jul 01 04:18:43 EDT 2025 Fri Feb 21 02:36:25 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | PMN-MDSCs Prognosis M-MDSCs Acute myeloid leukemia Neutrophil maturation stages |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c359t-c63c008aea579bd582043be5ac004822185acde85a70a88371d8adcdae86649f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 39673675 |
| PQID | 3144440816 |
| PQPubID | 54085 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_3154267502 proquest_miscellaneous_3146777403 proquest_journals_3144440816 pubmed_primary_39673675 crossref_primary_10_1007_s12026_024_09558_6 springer_journals_10_1007_s12026_024_09558_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-12-01 |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: 2025-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States – name: Totowa |
| PublicationTitle | Immunologic research |
| PublicationTitleAbbrev | Immunol Res |
| PublicationTitleAlternate | Immunol Res |
| PublicationYear | 2025 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | S Hegde (9558_CR10) 2021; 54 9558_CR20 L Tang (9558_CR38) 2020; 26 L Vago (9558_CR5) 2020; 130 JC Zhao (9558_CR29) 2022; 52 H Kiyoi (9558_CR30) 2020; 111 L Ai (9558_CR7) 2018; 18 U Creutzig (9558_CR22) 2013; 122 AJ Barrett (9558_CR6) 2020; 188 MM Yaseen (9558_CR12) 2021; 15 J Wang (9558_CR34) 2019; 9 AM Testi (9558_CR23) 2018; 132 F Veglia (9558_CR37) 2021; 218 H-M Chen (9558_CR33) 2015; 21 C Ruan (9558_CR35) 2022; 148 S Sampath (9558_CR39) 2018; 9 C Bergenfelz (9558_CR41) 2020; 10 V Greifenberg (9558_CR32) 2009; 39 M Rickmann (9558_CR31) 2013; 92 K Li (9558_CR9) 2021; 6 P Peterlin (9558_CR17) 2022; 26 F Thol (9558_CR4) 2020; 21 AA Al-Khami (9558_CR13) 2017; 6 JJM van Dongen (9558_CR26) 2012; 26 S Tettamanti (9558_CR27) 2022; 36 A Khwaja (9558_CR1) 2022; 2 EM Groarke (9558_CR43) 2019; 35 T Condamine (9558_CR14) 2016; 1 H Mahmood (9558_CR52) 2014; 7 S Meshinchi (9558_CR24) 2001; 97 F Veglia (9558_CR45) 2018; 19 EG van Lochem (9558_CR44) 2004; 60 CR Millrud (9558_CR47) 2017; 8 JM Rowe (9558_CR2) 2022; 107 T Büchner (9558_CR3) 2012; 30 T Kalina (9558_CR25) 2012; 26 S Brandau (9558_CR46) 2011; 89 O Marini (9558_CR49) 2016; 7 J Torres-Ruiz (9558_CR40) 2022; 62 L Mezquita (9558_CR50) 2021; 151 JY Sagiv (9558_CR51) 2015; 10 V Bronte (9558_CR11) 2016; 7 H Döhner (9558_CR19) 2017; 129 EM Rego (9558_CR21) 2013; 121 J Pillay (9558_CR48) 2013; 70 S Lang (9558_CR15) 2018; 24 SY Hyun (9558_CR18) 2020; 9 C Perez (9558_CR16) 2020; 136 C Groth (9558_CR8) 2019; 120 A Isidori (9558_CR28) 2021; 11 WW Pang (9558_CR42) 2011; 108 M Mehmeti-Ajradini (9558_CR36) 2020; 3 |
| References_xml | – volume: 9 start-page: 4893 year: 2019 ident: 9558_CR34 publication-title: Theranostics doi: 10.7150/thno.36037 – volume: 60 start-page: 1 year: 2004 ident: 9558_CR44 publication-title: Cytometry B Clin Cytom doi: 10.1002/cyto.b.20008 – volume: 92 start-page: 1079 year: 2013 ident: 9558_CR31 publication-title: Ann Hematol doi: 10.1007/s00277-013-1744-y – volume: 26 start-page: 1763 year: 2020 ident: 9558_CR38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-3003 – volume: 10 start-page: 109 year: 2020 ident: 9558_CR41 publication-title: Front Oncol doi: 10.3389/fonc.2020.00109 – volume: 121 start-page: 1935 year: 2013 ident: 9558_CR21 publication-title: Blood. doi: 10.1182/blood-2012-08-449918 – volume: 70 start-page: 3813 year: 2013 ident: 9558_CR48 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-013-1286-4 – volume: 18 start-page: 1220 year: 2018 ident: 9558_CR7 publication-title: BMC Cancer doi: 10.1186/s12885-018-5086-y – volume: 26 start-page: 1986 year: 2012 ident: 9558_CR25 publication-title: Leukemia doi: 10.1038/leu.2012.122 – volume: 188 start-page: 147 year: 2020 ident: 9558_CR6 publication-title: Br J Haematol doi: 10.1111/bjh.16310 – volume: 148 start-page: 1551 year: 2022 ident: 9558_CR35 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-022-03957-8 – volume: 130 start-page: 1552 year: 2020 ident: 9558_CR5 publication-title: J Clin Invest doi: 10.1172/JCI129204 – volume: 3 start-page: e202000893 year: 2020 ident: 9558_CR36 publication-title: Life Sci Alliance doi: 10.26508/lsa.202000893 – volume: 218 start-page: e20201803 year: 2021 ident: 9558_CR37 publication-title: J Exp Med doi: 10.1084/jem.20201803 – volume: 15 start-page: 232 year: 2021 ident: 9558_CR12 publication-title: Front Med doi: 10.1007/s11684-020-0797-2 – volume: 151 start-page: 211 year: 2021 ident: 9558_CR50 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.03.011 – volume: 129 start-page: 424 year: 2017 ident: 9558_CR19 publication-title: Blood doi: 10.1182/blood-2016-08-733196 – volume: 107 start-page: 3 year: 2022 ident: 9558_CR2 publication-title: Haematologica doi: 10.3324/haematol.2021.280161 – volume: 30 start-page: 3604 year: 2012 ident: 9558_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.2907 – volume: 108 start-page: 20012 year: 2011 ident: 9558_CR42 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1116110108 – volume: 1 start-page: aaf8943 year: 2016 ident: 9558_CR14 publication-title: Sci Immunol doi: 10.1126/sciimmunol.aaf8943 – volume: 24 start-page: 4834 year: 2018 ident: 9558_CR15 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3726 – volume: 9 start-page: 11279 year: 2018 ident: 9558_CR39 publication-title: Oncotarget doi: 10.18632/oncotarget.24397 – volume: 6 start-page: e1344804 year: 2017 ident: 9558_CR13 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1344804 – volume: 39 start-page: 2865 year: 2009 ident: 9558_CR32 publication-title: Eur J Immunol doi: 10.1002/eji.200939486 – volume: 26 start-page: 5486 year: 2022 ident: 9558_CR17 publication-title: J Cell Mol Med doi: 10.1111/jcmm.17576 – volume: 10 start-page: 562 year: 2015 ident: 9558_CR51 publication-title: Cell Rep doi: 10.1016/j.celrep.2014.12.039 – volume: 52 start-page: 100905 year: 2022 ident: 9558_CR29 publication-title: Blood Rev doi: 10.1016/j.blre.2021.100905 – volume: 54 start-page: 875 year: 2021 ident: 9558_CR10 publication-title: Immunity doi: 10.1016/j.immuni.2021.04.004 – volume: 26 start-page: 1908 year: 2012 ident: 9558_CR26 publication-title: Leukemia doi: 10.1038/leu.2012.120 – ident: 9558_CR20 – volume: 11 start-page: 656218 year: 2021 ident: 9558_CR28 publication-title: Front Oncol doi: 10.3389/fonc.2021.656218 – volume: 89 start-page: 311 year: 2011 ident: 9558_CR46 publication-title: J Leukoc Biol doi: 10.1189/jlb.0310162 – volume: 2 start-page: 16010 year: 2022 ident: 9558_CR1 publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.10 – volume: 122 start-page: 37 year: 2013 ident: 9558_CR22 publication-title: Blood doi: 10.1182/blood-2013-02-484097 – volume: 111 start-page: 312 year: 2020 ident: 9558_CR30 publication-title: Cancer Sci doi: 10.1111/cas.14274 – volume: 62 start-page: 775 year: 2022 ident: 9558_CR40 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keac374 – volume: 7 start-page: 3 year: 2014 ident: 9558_CR52 publication-title: J Hematop doi: 10.1007/s12308-014-0198-z – volume: 21 start-page: 66 year: 2020 ident: 9558_CR4 publication-title: Cur Treat Options Oncol doi: 10.1007/s11864-020-00765-5 – volume: 21 start-page: 4073 year: 2015 ident: 9558_CR33 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2742 – volume: 36 start-page: 13 year: 2022 ident: 9558_CR27 publication-title: Leukemia doi: 10.1038/s41375-021-01350-x – volume: 8 start-page: 3649 year: 2017 ident: 9558_CR47 publication-title: Oncotarget doi: 10.18632/oncotarget.12278 – volume: 132 start-page: 405 year: 2018 ident: 9558_CR23 publication-title: Blood doi: 10.1182/blood-2018-03-836528 – volume: 7 start-page: 27676 year: 2016 ident: 9558_CR49 publication-title: Oncotarget doi: 10.18632/oncotarget.8507 – volume: 9 start-page: 7007 year: 2020 ident: 9558_CR18 publication-title: Cancer Med doi: 10.1002/cam4.3360 – volume: 6 start-page: 362 year: 2021 ident: 9558_CR9 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-021-00670-9 – volume: 136 start-page: 199 year: 2020 ident: 9558_CR16 publication-title: Blood doi: 10.1182/blood.2019004537 – volume: 19 start-page: 108 year: 2018 ident: 9558_CR45 publication-title: Nat Immunol doi: 10.1038/s41590-017-0022-x – volume: 7 start-page: 12150 year: 2016 ident: 9558_CR11 publication-title: Nat Commun doi: 10.1038/ncomms12150 – volume: 35 start-page: 285 year: 2019 ident: 9558_CR43 publication-title: Clin Geriatr Med doi: 10.1016/j.cger.2019.03.001 – volume: 120 start-page: 16 year: 2019 ident: 9558_CR8 publication-title: Br J Cancer doi: 10.1038/s41416-018-0333-1 – volume: 97 start-page: 89 year: 2001 ident: 9558_CR24 publication-title: Blood doi: 10.1182/blood.v97.1.89 |
| SSID | ssj0016443 |
| Score | 2.4350502 |
| Snippet | Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 11 |
| SubjectTerms | Acute myeloid leukemia Adaptive immunity Adult Aged Aged, 80 and over Allergology Antigens, CD - metabolism Biomedical and Life Sciences Biomedicine CD11b antigen CD13 antigen CD36 antigen CD45 antigen Cell survival Female Flow Cytometry fms-Like Tyrosine Kinase 3 - genetics fms-Like Tyrosine Kinase 3 - metabolism Humans Immunology Immunophenotyping Internal Medicine Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - pathology Leukocytes (neutrophilic) Lymphocytes T Male Maturation Medical prognosis Medicine/Public Health Middle Aged Monocytes Mutation myeloid leukemia Myeloid-Derived Suppressor Cells - immunology neoplasm progression neutrophils Neutrophils - immunology Prognosis Retrospective Studies Suppressor cells T-Lymphocytes - immunology Young Adult |
| Title | Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations |
| URI | https://link.springer.com/article/10.1007/s12026-024-09558-6 https://www.ncbi.nlm.nih.gov/pubmed/39673675 https://www.proquest.com/docview/3144440816 https://www.proquest.com/docview/3146777403 https://www.proquest.com/docview/3154267502 |
| Volume | 73 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF-0RelL0fp1tZYVfNOFXDb7cb5dpWdRWnzw4HwKm-wEQq9JuSSF-yf8m53ZS-6QquBLEtghLDuz2d9k5jfD2LsIYlmYLBPeFiCSooiFSworXGYBpCqScSCFXV7pi3nyZaEWPSmsGbLdh5Bk-FLvyG7op1PCbCKobJoV-iHbV-S7oxXP4-k2doAnfIgrozGK2JhFT5X58zt-P47uYcx78dFw7MyesMMeL_LpRsFP2QOojtijTQfJ9RF7fNnHxp-xn99WNWXNoSCnEt7A64LfrGFZl154NLQ78LzpbkPma70Sy_IaOP23b3hZcZd3LQzifAndNdyU7iMONeS-N5x4KLwkNglVIqjqdk1MK-4qzwd2Jc-p1UefXPeczWfn3z9diL7bgsilmrQi1zJHQODAKTPJvLLEms1AuZx2eYxQAB894NVEzqJfO_bW-dw7sFonk0K-YHtVXcErxo00UeSg0DZJEg8-Q3llvPOZji2MzYi9HxY9vd0U1Uh35ZNJRSmqKA0qSvWInQx6SfsN1qQSHUFqlj3G4bfbYdwatG6ugroLMtogvI3kv2QUYhSETfGIvdzofDslOaGkN6NG7MNgBLsJ_H2-x_8n_podxNRTOKTInLC9dtXBGwQ6bXbK9qezs7Mrun_-8fX8NNj5L92C-oQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fa9RAEF604o-XotXqadUVfNOFXJL9cb6V0nJqr_jQg3sLm-wshF6TckmE-yf8m53ZS-6QWsGXENghLJnZ7LeZ75th7GMEceJ1ngtnPIjU-1jY1BthcwOQSJ-OgyhsdqGm8_TbQi56UVgzsN2HlGT4Uu_EbnhOJ8JsKqhsmhHqPnuAYMAQkWseH29zB7jDh7wyBqOItV70Upm_P-PP7egWxryVHw3bztlTtt_jRX68cfAzdg-qA_Zw00FyfcAezfrc-HP268eqJtYcGnIq4Q289vx6Dcu6dMJhoP0Ex5vuJjBf65VYllfA6b99w8uK26JrYTDnS-iu4Lq0X3CooeN7w0mHwktSk1Algqpu16S04rZyfFBX8oJaffTkuhdsfnZ6eTIVfbcFUSRy0opCJQUCAgtW6knupCHVbA7SFrTKY4QCeOsArzqyBs-1Y2esK5wFo1Q68ckh26vqCl4xrhMdRRa8MmmaOnA52kvtrMtVbGCsR-zT8NKzm01RjWxXPplclKGLsuCiTI3Y0eCXrF9gTZbgQZCaZY9x-MN2GJcGvTdbQd0FG6UR3kbJv2wkYhSETfGIvdz4fDulZEKkNy1H7PMQBLsJ3D3f1_9n_p49nl7OzrPzrxff37AnMfUXDnSZI7bXrjp4i6Cnzd-FGP8NIa76Zw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagiIoLgvLaUsBI3MBqEjuxl1sFrMqjVQ-stLfIicdS1G2y2iRI-yf6m5nJYxdUQOISRfIosjxj-5vMfDOMvQkgkl5nmXDGg1DeR8Iqb4TNDICMvQo7UtjZeXI6V18W8eIXFn-X7T6GJHtOA1VpKpvjlfPHO-Ib-uyUPKsElVAzIrnN7uBxHJJdz6OTbRwBb_suxoyGKSKtFwNt5s_f-P1quoE3b8RKuyto9oDdH7AjP-mV_ZDdgvKA3e27SW4O2P7ZECd_xK4v1hVl0KEgp3LewCvPrzawrAonHBrdD3C8blddFmy1FsviEjj9w695UXKbtw2M4nwJ7SVcFfY9DtXkytecOCm8IGYJVSUoq2ZDrCtuS8dHpiXPqe3HkGj3mM1nn75_OBVD5wWRy3jaiDyROYIDCzbW08zFhhi0GcQ2px0fISzAVwf41IE16OOGzliXOwsmSdTUyydsr6xKeMa4ljoILPjEKKUcuAzlY-2sy5LIQKgn7O246OmqL7CR7kopk4pSVFHaqShNJuxo1Es6bLY6legUUuPsEIdfb4dxm9C62RKqtpNJNELdQP5LJka8ghAqmrCnvc63U5JTSoDT8YS9G41gN4G_z_fw_8Rfsf2Lj7P02-fzr8_ZvYhaDXeZM0dsr1m38ALxT5O97Ez8J1TJ_qM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+myeloid-derived+suppressor-like+cells+in+acute+myeloid+leukemia%3A+insights+from+immunophenotyping+and+clinical+correlations&rft.jtitle=Immunologic+research&rft.date=2025-12-01&rft.pub=Springer+Nature+B.V&rft.issn=0257-277X&rft.eissn=1559-0755&rft.volume=73&rft.issue=1&rft.spage=11&rft_id=info:doi/10.1007%2Fs12026-024-09558-6&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0257-277X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0257-277X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0257-277X&client=summon |